Treatment with Topical Azole Antifungal Therapy
Treat this patient with an intravaginal azole antifungal agent—this is uncomplicated vulvovaginal candidiasis confirmed by KOH prep showing branching hyphae (yeast/pseudohyphae), and topical azoles achieve 80-90% cure rates with minimal side effects. 1
Clinical Reasoning
This 30-year-old woman presents with the classic triad of vulvovaginal candidiasis (VVC):
- Curd-like white discharge (pathognomonic appearance)
- Vaginal itching (most specific symptom for VVC)
- Vaginal erythema with absence of malodor
The KOH prep showing branching hyphae confirms the diagnosis—this demonstrates yeasts or pseudohyphae, which is diagnostic when combined with symptoms 1. The lack of malodorous discharge helps exclude bacterial vaginosis, and the curd-like appearance is characteristic of Candida rather than Trichomonas.
Recommended Treatment Options
First-line intravaginal azole regimens (all equally effective) 1:
Over-the-Counter Options:
- Clotrimazole 1% cream 5g intravaginally for 7-14 days
- Miconazole 2% cream 5g intravaginally for 7 days
- Miconazole 200mg suppository once daily for 3 days
- Tioconazole 6.5% ointment 5g single application
Prescription Options:
- Terconazole 0.4% cream 5g intravaginally for 7 days
- Terconazole 80mg suppository once daily for 3 days
Oral Alternative:
Why This Approach
Topical azoles are preferred over oral therapy because they provide equally effective treatment (80-90% cure rates) with fewer systemic side effects 1. While oral fluconazole offers convenience, topical agents avoid potential drug interactions and rare hepatotoxicity concerns 3.
This is uncomplicated VVC based on:
- First episode presentation (no history of recurrence mentioned)
- Immunocompetent host (no HIV, diabetes, or immunosuppression noted)
- Likely Candida albicans (most common species in uncomplicated cases)
- Normal clinical severity
Short-course regimens (1-3 days) effectively treat uncomplicated VVC 1, though 7-day courses may be considered for more complete symptom resolution 4.
Important Clinical Caveats
Do NOT treat the sexual partner unless he develops symptomatic balanitis (penile erythema with pruritus). VVC is not sexually transmitted, and partner treatment does not reduce recurrence rates 3, 1.
No follow-up needed if symptoms resolve. Instruct the patient to return only if symptoms persist after completing therapy or recur within 2 months 1.
Watch for treatment failure, which should prompt:
- Consideration of non-albicans species (though less likely in first episode)
- Evaluation for predisposing factors (diabetes, immunosuppression, antibiotic use)
- Possible azole resistance (rare in first episodes)
The mild intermittent dysuria is external dysuria from vulvar inflammation, not a urinary tract infection—this will resolve with antifungal treatment of the VVC 3, 2.